TP53 mutations were observed in 50% of the HGSOC samples unlike in the TCGA cohort where 96% of ovarian cancers were TP53 mutated (Network and The Cancer Genome Atlas Research Network, 2011). This evidence concerns the gene TP53 and ovarian carcinoma.